As of 8:00pm ET
| -0.04 / -2.25%|
The 3 analysts offering 12-month price forecasts for Rexahn Pharmaceuticals Inc have a median target of 13.00, with a high estimate of 19.50 and a low estimate of 6.00. The median estimate represents a +647.13% increase from the last price of 1.74.
The current consensus among 3 polled investment analysts is to Buy stock in Rexahn Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.